TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $18.68 million versus the consensus estimate of $28.98 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.